[11C]NOP-1A and Cocaine Use Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-10-30

Study Completion Date

2019-02-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this study is to compared \[C-11\]NOP-1A binding in recently abstinent cocaine use disorders and controls.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Imaging CRF X NOP Interactions in CUD

NCT05008146

Cocaine Use Disorder

RECRUITING EARLY_PHASE1

Cocaine Abuse and ADHD - 10

NCT00000275

Cocaine-Related Disorders

COMPLETED PHASE2

Propranolol for Treatment of Cocaine Addiction - 2

NCT00000197

Cocaine-Related Disorders

COMPLETED PHASE2

Cocaine Use Disorder and Cortical Dopamine

NCT03349606

Cocaine Dependence

COMPLETED EARLY_PHASE1

Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

NCT05610072

Cocaine Use Disorder Opioid Use Disorder Stimulant Use Disorder

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This will allow for understanding brain stress and anti-stress mechanisms that underlie abuse of cocaine in humans.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cocaine Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

\[C-11\]NOP-1A

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cocaine use disorders

PET scan

Group Type EXPERIMENTAL

[C-11]

Intervention Type RADIATION

Radiolabel

NOP-1A

Intervention Type DRUG

Tracer

Controls

PET scan

Group Type EXPERIMENTAL

[C-11]

Intervention Type RADIATION

Radiolabel

NOP-1A

Intervention Type DRUG

Tracer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[C-11]

Radiolabel

Intervention Type RADIATION

NOP-1A

Tracer

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Males or Females 18-50
2. Fulfill DSM-5 Diagnosis for Cocaine use disorder
3. Medically Healthy

1. Males or Females 18-50
2. Absence of present or past psychiatric conditions (including alcohol or drug use disorders)
3. A negative urine drug screen
4. Medically Healthy

Exclusion Criteria

1. Pregnancy or lactation
2. Comorbid medical, psychiatric, drug use disorders (other than cocaine, tobacco use, and recreational marijuana/alcohol use)
3. Metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan
4. Currently employed as radiation worker; or participation in radioactive drug research protocols within the previous year
5. Currently on any psychotropic medications that can influence nociceptin transmission in the brain (e.g., morphine, suboxone, SSRIs, etc.)

\[B\] Healthy controls

1. Pregnancy or lactation
2. Medical, psychiatric or drug \& alcohol use disorders
3. Metal implants or paramagnetic objects contained within the body which may interfere with the MRI scan
4. Currently employed as radiation worker; or participation in radioactive drug research protocols within the previous year
5. Currently on any psychotropic medications that can influence nociceptin transmission in the brain
6. Family history of a psychotic disorder, manic episode, drug use disorders in first-degree relatives.

Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes